28 filings
8-K
NUVL
Nuvalent Inc - Ordinary Shares
14 Jun 24
Submission of Matters to a Vote of Security Holders
4:05pm
8-K
NUVL
Nuvalent Inc - Ordinary Shares
16 May 24
Other Events
4:10pm
8-K
NUVL
Nuvalent Inc - Ordinary Shares
9 May 24
Nuvalent Highlights Pipeline Progress, Reiterates Key Anticipated Milestones, and Reports First Quarter 2024 Financial Results
6:37am
8-K
NUVL
Nuvalent Inc - Ordinary Shares
27 Feb 24
Nuvalent Highlights Pipeline Progress, Reiterates Key Anticipated Milestones and Reports Fourth Quarter and Full Year 2023 Financial Results
6:38am
8-K
NUVL
Nuvalent Inc - Ordinary Shares
9 Jan 24
Nuvalent Announces “OnTarget 2026” Operating Plan and Key Anticipated Milestones
4:40pm
8-K
f3raahsdx17w
14 Nov 23
Nuvalent Highlights Corporate and Pipeline Achievements and Reports Third Quarter
6:45am
8-K
xwwc0cntqtvhb84a
17 Oct 23
Nuvalent Announces Pricing of Public Offering of Common Stock
4:07pm
8-K
r7b07sulsc5r2xz
13 Oct 23
Nuvalent Reports Preliminary Phase 1 Clinical Data from ALKOVE-1 Trial
6:40am
8-K
qhlnz27lzo
4 Oct 23
Other Events
4:05pm
8-K
885j inao2pau747l5zj
10 Aug 23
Nuvalent Highlights Pipeline Progress and Reports Second Quarter 2023 Financial Results
6:45am
8-K
7hcd959w
16 Jun 23
Amendments to Articles of Incorporation or Bylaws
4:08pm
8-K
2zp8u
11 May 23
Nuvalent Announces Anticipated Timing of Preliminary Phase 1 Dose-Escalation Data for NVL-655 and Reports First Quarter 2023 Financial Results
6:39am
8-K
2jz88njg abs
16 Mar 23
Nuvalent Highlights Pipeline and Business Progress and Reports Fourth Quarter and Full Year 2022 Financial Results
6:36am
8-K
0hpput nfpk01vlwqu
10 Mar 23
Regulation FD Disclosure
8:38pm
8-K
n2y8w
10 Nov 22
Nuvalent Reviews Corporate and Pipeline Achievements and Reports Third Quarter 2022 Financial Results
6:37am
8-K
uidr gstey76rdbgylo2
1 Nov 22
Nuvalent Announces Pricing of Public Offering of Common Stock
5:19pm
8-K
3hql msfs
28 Oct 22
Other Events
6:05am
8-K
mr7nks k2
6 Oct 22
Departure of Directors or Certain Officers
4:16pm
8-K
arzmv9 zlo9a
10 Aug 22
Nuvalent Highlights Execution Across Pipeline of Novel Kinase Inhibitors and Reports Second Quarter 2022 Financial Results
12:00am
8-K
o7waffx bf9kp9m
21 Jun 22
Submission of Matters to a Vote of Security Holders
4:30pm